Cardiac HDAC3 Disruption Contributes to HDAC Inhibitor-Induced QT Prolongation
Histone deacetylase (HDAC) inhibitors are approved for cancer treatment and are being investigated for a wide range of other diseases. Despite their therapeutic promise, clinical studies have reported cardiac side effects, particularly electrocardiogram (EKG) abnormalities, with QT interval prolonga...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI AG
2026-05-01
|
| Schriftenreihe: | Cells |
| Schlagworte: | |
| Online-Zugang: | https://www.mdpi.com/2073-4409/15/10/902 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|